BeiGene, Ltd. (NASDAQ:BGNE) Given Average Rating of “Moderate Buy” by Analysts

BeiGene, Ltd. (NASDAQ:BGNE) has been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $253.69.

Several research firms have commented on BGNE. Morgan Stanley reiterated an “overweight” rating and issued a $300.00 price objective on shares of BeiGene in a research note on Tuesday, December 3rd. JPMorgan Chase & Co. lifted their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. StockNews.com assumed coverage on BeiGene in a research report on Sunday, January 19th. They issued a “hold” rating on the stock. Finally, TD Cowen raised their target price on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $187.27, for a total transaction of $194,202,173.59. Following the sale, the director now directly owns 791,493 shares in the company, valued at approximately $148,222,894.11. The trade was a 56.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Xiaodong Wang sold 40,468 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total value of $7,692,966.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,119,245 shares of company stock valued at $209,700,084. 7.43% of the stock is owned by insiders.

Institutional Investors Weigh In On BeiGene

Several hedge funds and other institutional investors have recently modified their holdings of BGNE. Blue Trust Inc. grew its position in BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after buying an additional 75 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of BeiGene during the third quarter worth about $36,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BeiGene in the third quarter worth approximately $67,000. SG Americas Securities LLC purchased a new stake in BeiGene in the third quarter valued at approximately $105,000. Finally, PFG Investments LLC bought a new stake in BeiGene during the third quarter valued at approximately $210,000. 48.55% of the stock is currently owned by institutional investors.

BeiGene Price Performance

BeiGene has a fifty-two week low of $126.97 and a fifty-two week high of $248.16. The firm has a market cap of $18.03 billion, a price-to-earnings ratio of -22.42 and a beta of 0.57. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $194.32 and a 200-day simple moving average of $188.98.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 earnings per share. As a group, analysts expect that BeiGene will post -5.64 EPS for the current year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.